GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (NYSE:DVA) » Definitions » GF Value

DVA (DaVita) GF Value : $125.55 (As of Mar. 27, 2025)


View and export this data going back to 1995. Start your Free Trial

What is DaVita GF Value?

As of today (2025-03-27), DaVita's share price is $152.50. DaVita's GF Value is $125.55. Therefore, DaVita's Price-to-GF-Value for today is 1.21. Based on the relationship between the current stock price and the GF Value, GuruFocus believes DaVita is Modestly Overvalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

  1. We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
  2. We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
  3. Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.


DaVita  (NYSE:DVA) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

DaVita's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=152.50/125.55
=1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DaVita GF Value Related Terms

Thank you for viewing the detailed overview of DaVita's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


DaVita Business Description

Traded in Other Exchanges
Address
2000 16th Street, Denver, CO, USA, 80202
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
Executives
Berkshire Hathaway Inc 10 percent owner 3555 FARNAM STREET, OMAHA NE 68131
Javier Rodriguez officer: Chief Executive Officer, DKC 601 HAWAII ST., EL SEGUNDO CA 90245
Joel Ackerman officer: Chief Financial Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Michael David Staffieri officer: Chief Operating Officer, DKC 2000 16TH STREET, DENVER CO 80202
Kathleen Alyce Waters officer: Chief Legal Officer C/O DAVITA INC., 2000 16TH STREET, DENVER CO 80202
Barbara J Desoer director CITIGROUP INC., 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
James O Hearty officer: Chief Compliance Officer 2000 16TH STREET, DENVER CO 80202
Christopher Michael Berry officer: Chief Accounting Officer C/O SONDER HOLDINGS INC., 101 15TH ST., SAN FRANCISCO CA 94103
Wendy Lee Schoppert director 6105 TRENTON LANE NORTH, MINNEAPOLIS MN 55442
Phyllis R Yale director
Charles Berg director, officer: Executive Chair, DMG 48 MONROE TURNPIKE, TRUMBULL CT 06611
John M Nehra director 1119 ST PAUL ST, BALTIMORE MD 21202
Adam H Schechter director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jason M. Hollar director 3333 BEVERLY ROAD, HOFFMAN ESTATES IL 60179
Paula A Price director ONE CVS DRIVE, WOONSOCKET RI 02895